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Abstract. Patients with Hodgkin lymphoma treated with DNA
mechlorethamine and procarbazine in the MOPP regimen and with topoisomerase II inhibitors, 
such  as  etoposide  did  show  a  long
acute  myelogenous  leukaemia  (MDS/AML).  With  the  introduction  of  the  ABVD  (adriamycin, 
bleomycin,  vinblastine,  dacarbazine)  regimen,  this  risk  has  substantially  been  reduced.  In  this 
review,  different  experiences  are  discussed  to  determine  whethe
treatment in different cohorts of patients have reduced the overall risk of secondary MDS/AML. 
These data are drawn from large cohorts of patients treated over time with different therapies with 
an adequate follow-up. 
Introduction.  Patients  with  Hodgkin  lymphoma 
treated with DNA-breaking alkylating agents such as 
mechlorethamine  and  procarbazine  in  the  MOPP 
regimen
1 and with topoisomerase II inhibitors, such as 
etoposide  did  show  a  long-term  risk  of  developing 
therapy-related myelodysplasia and acute myelogenous 
leukaemia (MDS/AML).
2,3With the introduction of the 
ABVD  (adriamycin,  bleomycin,  vinblastine, 
dacarbazine) regimen,
4 this risk has substantially been 
reduced.
5 In  this  review,  different  experiences  are 
discussed to determine whether and how modifications 
of  treatment  in  different  cohorts  of  patients  have 
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Patients with Hodgkin lymphoma treated with DNA-breaking alkylating agents such as 
mechlorethamine and procarbazine in the MOPP regimen and with topoisomerase II inhibitors, 
such  as  etoposide  did  show  a  long-term risk  of  developing  therapy-related  myelodys
acute  myelogenous  leukaemia  (MDS/AML).  With  the  introduction  of  the  ABVD  (adriamycin, 
bleomycin,  vinblastine,  dacarbazine)  regimen,  this  risk  has  substantially  been  reduced.  In  this 
review,  different  experiences  are  discussed  to  determine  whether  and  how  modifications  of 
treatment in different cohorts of patients have reduced the overall risk of secondary MDS/AML. 
These data are drawn from large cohorts of patients treated over time with different therapies with 
Patients  with  Hodgkin  lymphoma 
breaking alkylating agents such as 
mechlorethamine  and  procarbazine  in  the  MOPP 
hibitors, such as 
term  risk  of  developing 
related myelodysplasia and acute myelogenous 
With the introduction of the 
ABVD  (adriamycin,  bleomycin,  vinblastine, 
this risk has substantially been 
In  this  review,  different  experiences  are 
discussed to determine whether and how modifications 
of  treatment  in  different  cohorts  of  patients  have 
reduced  the  overall  risk  of  secondary  MDS/AML. 
These  data  are  drawn  from  large  cohorts  of patients 
treated  over  time  with  different  therapies  with  an 
adequate follow-up. 
Historical  data.  In  a  large  cooperative  case
study to assess the relative risk associated with several 
factors including age, splenectomy, com
therapy and cumulative dosage of alkylating agents and 
nitrosurea  derivatives,  we  observed  that  the  risk  of 
leukemia  in  patients  treated  for  Hodgkin  lymphoma 
was  significantly  higher  after  combined  modality
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n  from  large  cohorts  of patients 
treated  over  time  with  different  therapies  with  an 
In  a  large  cooperative  case-control 
study to assess the relative risk associated with several 
factors including age, splenectomy, combined modality 
therapy and cumulative dosage of alkylating agents and 
nitrosurea  derivatives,  we  observed  that  the  risk  of 
leukemia  in  patients  treated  for  Hodgkin  lymphoma 
was  significantly  higher  after  combined  modalityMediterr J Hematol Infect Dis 2012; 4: Open Journal System
Table 1. Logistic regression analysis of risk of leukemia in HL
Variables OR 95% CI P value
Age > 40 years 1.1 0.7-1.5 ns
Stage III-IV 2.3 1.1-5 0.03
Splenectomy 1.4 0.6-3.3 ns
MOPP alone 4.1 1.1-2.2 0.05
CT+RT 6.4 1.4-29 0.02
MOPP + EF-RT 5.9 2.3-12 0.001
MOPP + lomustine 8 4-25 0.05
MOPP and splenectomy 7.2 2.1-25 0.002
HL = Hodgkin lymphoma; ns = not statistically different 
programs  than  after  chemotherapy  alone  (mostly  the 
MOPP regimen) and was correlated with the extent of 
radiotherapy and type and duration of chemotherapy.
2
Table 1 illustrates the results of the logistic regression 
analysis in this series of 1659 patients followed for a 
median time of 10 years.
2 Age over 40 years was not 
an  independent  risk  variable  for  leukaemia,  while  a 
borderline  significance  was  observed  between 
increasing  age  and  increased  risk  of  subsequent 
leukaemia when the age was analyzed as a continuous 
variable.  At  variance,  a  significant  influence  was 
observed for advanced-stage versus early-stage disease 
(OR = 2.3; p = 0.03), for combined modality therapy 
(OR = 6.4; p = 0.02) and CT alone (OR = 4.1; p = 
0.05)  versus  RT  alone  as  reference  group.  In  the 
combined  modality  therapy  group,  the  MOPP 
combination  +  extended-field  radiotherapy  (EF-RT), 
either as adjuvant or salvage therapy, conferred a risk 
of  leukemia  5.9  times  higher  than  that  given  by 
chemotherapy  without  alkylating  agents  and 
procarbazine  (p  =  0.001).  Among  patients  who 
received  salvage  therapy,  the  use  of  nitrosourea-
containing  regimens  significantly  increased  the  risk 
compared to that after MOPP or MOPP alternating to 
ABVD (OR = 8; p = 0.05). 
Splenectomy was influential only in patients who had 
received MOPP chemotherapy (OR = 7.2; p = 0.002). 
A combined modality therapy including MOPP and RT 
(MOPP followed by adjuvant RT or RT followed by 
MOPP,  or  MOPP  as  salvage  after  RT)  conveyed  a 
higher  risk  of  leukemia  than  alternating  MOPP  and 
ABVD + RT or ABVD alone + RT (p = 0.002; Figure 
1). Likewise, in the 25-year experience of the National 
Cancer  Institute  of  Milan,  the  cumulative  risk  of 
secondary  MDS/AML  after  MOPP  was  6.2%  versus 
1.7% in patients treated with ABVD.
6 In conclusion, 
the “historical” risk factors for secondary MDS/AML 
in  Hodgkin  lymphoma  were  the  use  of 
mechlorethamine and procarbazine combined with EF-
RT,  splenectomy  in  patients  receiving  MOPP  and 
salvage regimens containing nitrosurea derivatives. 
How the risk of MDS/AML has been reduced. We 
have modified over time our therapeutic approach in 
Hodgkin  lymphoma  reducing  (with  the  alternating
Figure 1. Risk of MDS/AML in Hodgkin lymphoma after combined modality treatment according to the type of chemotherapy.Mediterr J Hematol Infect Dis 2012; 4: Open Journal System
MOPP and ABVD regimens) and eventually abolishing 
mechlorethamine and procarbazine and limiting doses 
and  volumes  of  radiotherapy.  We  analyzed  three 
different cohorts of patients treated at our Institution 
from 1972 to 2003. The first cohort (A) includes 202 
patients treated from 1972 to 1982 with MOPP ± RT; 
46%  of  them  received  MOPP  alone  for  advanced 
disease and 54% MOPP + EF-RT. The second cohort 
(B) includes 231 patients treated from 1983 to 1995 
with  alternated  MOPP  and  ABVD  (4+4  cycles)  for 
advanced disease; 24% of them had been given RT. 
The third cohort (C) includes 207 patients treated from 
1996 to 2003 (median FU: 12 yrs) with ABVD alone ± 
RT; 120 patients of this cohort (58%) received 4 cycles 
of ABVD and limited RT for early stage disease, while 
42%  received  8  cycles  of  ABVD  and  no  RT  for 
advanced-stage disease. Over a median follow-up of 12 
years, the overall incidence of secondary MDS/AML 
was  2.6%  (17  out  of  640  total  patients).  Table  2
illustrates the distribution of MDS/AML cases in the 
three different cohorts of treatment. The incidence of 
secondary MDS/AML in patients of the cohort A was 
6% (12 out 202 patients), with a 10-year actuarial risk 
of  5.5%;  most  of  the  patients  developing  secondary 
leukemia  in  this  cohort  had  received  the  combined 
modality  treatment  as  a  first-line  treatment.  In  the 
cohort  B,  the  crude  rate  of  MDS/ASML  was  2.6%, 
with 10-year actuarial risk of 2%; 5 out of 6 patients 
developing  leukemia  in  this  cohort  had been  given 
salvage  therapy  containing  lomustine  for  relapse  or 
resistant  disease.  No  cases  of  secondary  MDS/AML 
occurred in this cohort of patients that had been spared 
alkylating agents and procarbazine and given limited 
RT.  A  similar  reduction  of  the  leukemogenic  risk 
according to therapy modifications over time has been 
registered  in  the  Stanford  University  series.
7 In  this 
experience,  three  cohorts  of  patients  have  been 
analyzed.  The  entire  first  cohort  of  patients  had 
received an alkylating-based therapy such as MOPP or 
PAVE  (procarbazine,  alkeran,  vinblastine)  and  RT 
(extended-field  RT  in  73%  of  total);  one  fourth  of 
patients  in  the  second  cohort  had  received  an 
alkylating-based CT, alone (26%) or with RT (37%), 
while  74%  had  received  a  non  alkylating-based  CT 
such as VBM (vinblastine, bleomycin, methotrexate) or 
ABVD + IF-RT (37%). The large majority of patients 
in  the  third  cohort  (88%  of  total)  had  received  the 
Stanford  V  regimen  +  RT.  The  incidence  of 
MDS/AML was significantly lower (0.3%) in the third 
cohort of patients compared to the others (6.7 % in the 
first  and  4.5%  in  the  second  cohort).  The  rarity  of 
MDS/AML in the Stanford V regimen cohort indicates 
that limiting the cumulative dose of alkylating-based 
CT  with  lesser  volumes  of  RT  has  significantly 
reduced the risk of subsequent leukemia. 
Table 2: Incidence of MDS/AML in Hodgkin lymphoma according 
to the era of treatment: The experience of the Hematological Clinic 
of Pavia.
Time and 
Treatment
No. of pts
(cohort)
Median 
FU (yrs)
No. 
MDS/AML
10-yr 
risk
1972-1983
MOPP ± RT 
202
(A) 20 12 (6%) 5.5%
1984-1996
MOPP/ABVD ± RT
231
(B) 16 6 (2.6%) 2%
1990-2003
ABVD ± RT
207
(C) 10 0 0
In  conclusion,  abolishing  mechlorethamine  and 
splenectomy  and  substantially  reducing  procarbazine
and radiotherapy has led to a consistent reduction of 
subsequent risk of leukemia in Hodgkin lymphoma. 
We have obtained a confirmation of the very low 
leukemogenic  risk  related  to  the  use  of  the  ABVD 
combination from the analysis of our series of patients 
with  clinical  stage  IA-IIA  nonbulky  Hodgkin 
lymphoma.  No  cases  of  secondary  MDS/AML  were 
observed among 120 patients treated with four cycles 
of ABVD + limited RT and followed for a median time 
of  15  years.
8 Furthermore,  no  cases  of  MDS/AML 
were  observed in  the  ABVD  arm  of  a  large  Italian 
randomized trial comparing first-line ABVD x 8 cycles 
versus  BEACOPP  (4  escalated+4  standard) in 
advanced-stage Hodgkin lymphoma.
9
Risk  of  MDS/AML  after  autologous  stem  cells 
transplantation.  An  increased  risk  of  secondary 
MDS/AML  has  been  observed  after  salvage  therapy 
with autologous bone marrow or peripheral stem cell 
transplantation  in  patients  with  resistant  or  relapsing 
Hodgkin  lymphoma;  the  reported  occurrence  of  this 
complication  was  quite  variable  in  the  different 
series.
10-13 Besides, in a recent report,
14 the comparison 
of  conventional  salvage  therapy  alone  versus 
conventional  therapy  followed  by  autologous 
hematopoietic  stem-cell  transplantation did  not  show 
an  increased  risk  of  second  neoplasms  (including 
MDS/AML)  after  the  high-dose  procedure.  In  our
experience,  the  5-year  actuarial  risk  of  MDS/AML 
after  autologous  stem  cell  transplant  in  resistant  or 
relapsing Hodgkin lymphoma was 2.9%, with a median 
latent  time  of  36  months from autologous  transplant 
and  a  median  72  months  from  the  time  of  the  first 
exposure  to  cytotoxic  therapy.  Cytogenetic  data  in 
these  cases  were  mostly  consistent  with  a  previous 
exposure to alkylating agents such chromosome 5 and 
or  7  alterations  and/or  deletions.  In  the  GITMO 
(Gruppo  Italiano  Trapianto  di  Midollo  Osseo) 
experience,  the  5-yr  actuarial  risk  of  subsequent Mediterr J Hematol Infect Dis 2012; 4: Open Journal System
MDS/AML was 3.2%, with a latent time of 28 months. 
In this experience, significant protective factors were 
represented  by  shortening  pre-tranplant  debulking 
chemotherapy, avoiding TBI as conditioning regimen 
and rescuing with a large number of CD34+ cells, with 
a cut off at 8 x 10
6/Kg. Taken together, the different 
data  on  the  risk  of  subsequent  MDS/AML  after 
autologous stem cells transplant in Hodgkin lymphoma 
indicate  the  critical  role  of  a  pre-tranplant 
chemotherapy  with  alkylating  agents  and  etoposide, 
while the high-dose procedure per se should not add to 
the  risk  when  an  appropriate  number  of  progenitors 
cells is provided for the hematological recovery. 
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